4161 Stock Overview
Engages in the production and sale of medical devices and reagents worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Bioptik Technology Incorporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$31.20 |
| 52 Week High | NT$39.55 |
| 52 Week Low | NT$27.50 |
| Beta | 0.39 |
| 1 Month Change | -4.88% |
| 3 Month Change | -15.10% |
| 1 Year Change | -5.45% |
| 3 Year Change | 17.00% |
| 5 Year Change | -4.21% |
| Change since IPO | -10.84% |
Recent News & Updates
Shareholder Returns
| 4161 | TW Medical Equipment | TW Market | |
|---|---|---|---|
| 7D | -3.4% | 2.1% | 0.5% |
| 1Y | -5.5% | -4.7% | 27.8% |
Return vs Industry: 4161 matched the TW Medical Equipment industry which returned -4.7% over the past year.
Return vs Market: 4161 underperformed the TW Market which returned 27.8% over the past year.
Price Volatility
| 4161 volatility | |
|---|---|
| 4161 Average Weekly Movement | 3.7% |
| Medical Equipment Industry Average Movement | 3.8% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4161 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4161's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | n/a | www.bioptik.com.tw |
Bioptik Technology Incorporation engages in the production and sale of medical devices and reagents worldwide. It offers EasyMate blood glucose monitoring systems; blood glucose/cholesterol/uric acid monitoring systems and its strips; and hyaluronic acid skin care products. The company also provides skin care products and dietary supplements, as well as biodiesel products.
Bioptik Technology Incorporation Fundamentals Summary
| 4161 fundamental statistics | |
|---|---|
| Market cap | NT$1.67b |
| Earnings (TTM) | NT$99.69m |
| Revenue (TTM) | NT$884.11m |
16.6x
P/E Ratio1.9x
P/S RatioIs 4161 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4161 income statement (TTM) | |
|---|---|
| Revenue | NT$884.11m |
| Cost of Revenue | NT$611.06m |
| Gross Profit | NT$273.05m |
| Other Expenses | NT$173.36m |
| Earnings | NT$99.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.88 |
| Gross Margin | 30.88% |
| Net Profit Margin | 11.28% |
| Debt/Equity Ratio | 49.5% |
How did 4161 perform over the long term?
See historical performance and comparisonDividends
2.2%
Current Dividend Yield36%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 10:11 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bioptik Technology Incorporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| PeiChing Lee | Yuanta Research |